To investigate the impact of 1,25 VD3 supplementation on liver function in the CDAA-induced NASH model, we assessed key liver function markers by measuring serum ALT (Figure 2A) and AST (Figure 2B) activities. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.